fashion -WSS

fashion

author：Wikipedia 2025-10-02 11:09:45 - browse：39

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Elevance, SCAN deals highlight health insurer acquisition scrutiny

WSS

Congress needs to close a vaccine

MD Anderson's Padmanee Sharma responds to research credit suit

New CMS data security rules will hurt Medicare, Medicaid research

Opioid cravings were reduced by anti

Finland to offer bird flu vaccine to select groups of people, a possible global first

Senators tussle over abortion against the backdrop of a presidential campaign

focus

fashion

hotspot

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Eli Lilly’s Zepbound improved liver scarring in mid

What does generative AI mean for health care? We asked experts

WATCH: Why do our ears pop?

Apple is now the first public company to be valued at $3 trillion

Secretariat’s lessons for human medicine

Continuity nursing helped my family in our darkest PICU moments

CMS got Medicare Advantage quality rating wrong, judge rules

Anesthesiologist group: stop taking Ozempic before surgery

Reporting on presidential health from Reagan to Trump and Biden

focus

New CMS data security rules will hurt Medicare, Medicaid research

The most pressing bird flu mysteries scientists want answered

'Little Tech' descents on D.C., wanting a say in how AI is regulated

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

CMS got Medicare Advantage quality rating wrong, judge rules

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

knowledge

entertainment

Wikipedia

focus